The Mental Health Crisis spirals. Psychedelic medicine advances. In 2022, "crisis" meets "opportunity".
Gold prices holding above $1,800
Gold prices are holding gains above $1,800 but is struggling to gain some bullish traction as consumer price pressures rise more than expected in December.
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
atai Life Sciences announces Investigational New Drug (IND) clearance from the FDA for PCN-101.
Gold, silver up as crude oil spikes up
Gold and silver futures prices are solidly higher in midday U.S. action Tuesday, boosted by positive daily outside markets that include sharply higher crude oil prices, a lower U.S. dollar index and a slight drop in U.S.
Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
Wesana announces a pre-IND meeting with the FDA for SANA-013 in March, it's lead drug candidate for Traumatic Brain Injury.
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Awakn announces strong results from its Phase II a/b clinical trial of a ketamine-assisted therapy for Alcohol Use Disorder (AUD).
Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
Field Trip announces receiving its USPTO patent for FT-104, including composition of matter.
Health Canada’s SAP Amendments: A Game-Changer For Psychedelic Medicine In Canada?
On January 5, 2022, Health Canada amendments to its Special Access Program has expanded access to psychedelic drug therapies. We explore the implications.
Nickel price hits highest in a month with inventories close to record lows
The nickel price rose on Monday to their highest level in more than one month, with inventories hovering close to record lows.
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds
Mydecine announces the use of AI to accelerate identification of drug candidates for psychedelics research.
Health Canada’s New SAP Rules: A Q&A With Numinus’ Payton Nyquvest
On January 4, 2022, amendments to Health Canada's Special Access Program took effect that explicitly include access to psychedelic medicine. We asked Numinus' Payton Nyquvest to connect the dots on the impact of these new rules.
The next big trend in mental health treatments? Psychedelic therapy.
Magic mushrooms for your well-being? If you haven't heard about psychedelics being used as a treatment for mental health disorders, this year may change that.
